Measuring the Utility of Prenatal Exome Sequencing Using the Clinician-Reported Genetic Testing Utility InDEx for Prenatal Care: A Retrospective Multicentre Study
In brief
Prenatal exome sequencing found a diagnosis in 42% of selected pregnancies
In this retrospective study of 115 pregnancies referred for testing at five Ontario clinics, prenatal exome sequencing produced a diagnosis in 41.7%. Clinicians rated testing as more useful when results were positive, more eligibility criteria were met, and the pregnancy was ongoing at result disclosure. The findings support its clinical value, but rely on clinician-reported assessments in a selected cohort.
- Journal
- Prenatal diagnosis (Q1)
- Published
- 11 November 2026
- Study design
- Retrospective cohort
- Evidence level
- Level 3, Low (CEBM 3b)
- Authors
- Robin Z Hayeems, Stephanie Luca, Bowen Xiao, David Chitayat, Erin Mathews, Sankavi Mohanathas, et al.
- PMID
- 43013894
- DOI
- 10.1002/pd.70306
Why clinicians should know about it
- Picked for Genetics (clinical) (top studies of the week, 15 November 2026): Prenatal exome yield and clinical utility inform genetic testing
Abstract
OBJECTIVE: To assess the diagnostic and clinical utility of prenatal exome sequencing (ES) in a cohort of pregnancies using the Clinician-reported Genetic testing Utility InDEx for Prenatal Care (C-GUIDE Prenatal). METHODS: Cases that met criteria for prenatal ES in Ontario, Canada were identified in 5 clinics. Clinicians assessed the utility of ES using C-GUIDE Prenatal, a clinician-reported measure of how genetic testing informs pregnancy and neonatal management. Case characteristics were summarized descriptively. C-GUIDE Prenatal total scores were calculated and regressed against clinically important variables using generalised estimating equations. RESULTS: Among 115 cases, the diagnostic yield was 41.7%. The mean C-GUIDE Prenatal score was 9.48 (SD 11.51). Compared with negative results, informative positive results were associated with an increase in C-GUIDE Prenatal score of 17.6 (p < 0.001). Compared to meeting one criterion for ES, meeting ≥ 3 criteria was associated with an increase in C-GUIDE Prenatal score of 3.8 (p < 0.05). Compared with pregnancies that were not ongoing at result disclosure, ongoing pregnancy was associated with an increase in the C-GUIDE Prenatal score of 2.8 (p < 0.001). CONCLUSION: Findings address a knowledge gap in the clinical value evidence base that informs policy and funding decision-making for prenatal genetic testing.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.